Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: Preferential cutaneous relapses but high cure rate with doxorubicin-based therapy

A. H. Sarris, Ira Braunschweig, L. J. Medeiros, M. Duvic, C. S. Ha, M. A. Rodriguez, F. B. Hagemeister, P. McLaughlin, J. Romaguera, J. Cox, F. Cabanillas

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: Establish frequency, presenting features, response and relapse patterns, and outcome of primary cutaneous non-Hodgkin's lymphoma (PCNHL). Patients and Methods: Review of untreated patients, older than 16 years, presenting between 1971 and 1993 with cutaneous lymphoma, not mycosis fungoides, and Ann Arbor stage I. Results: We identified 46 patients, 27 males, with median age of 57 years. Treatment was radiotherapy in 10 patients, doxorubicin-based therapy in 33 patients that was followed by radiotherapy in 25 patients, and other combination with radiotherapy in one patient. The complete response rate was 95%. After a median follow-up of 140 months (range, 61 to 284 months), 18 patients have relapsed, and 14 have died from lymphoma. The first failure was exclusively cutaneous in 50% of relapses. For the 44 treated patients, progression-free survival (PFS; actuarial ± SE) was 61% ± 7% and survival was 58% ± 9% at 12 years. For the 18 patients with diffuse large B-cell lymphoma, after doxorubicin-based regimens, PFS was 71% ± 12% (P = .0003) versus 0% after radiotherapy; survival was 77% ± 12% versus 25% ± 22% (P = 004), respectively. For the nine patients with follicular center-cell lymphoma treated with combined modality, the 12-year PFS was 89% ± 11% and survival 70% ± 18%. Conclusion: PCNHL is rare, and its first relapse is exclusively cutaneous in 50% of patients. Patients with diffuse large B-cell lymphoma are curable with doxorubicin-based regimens but not with radiotherapy. Prospective studies in PCNHL should define the cytogenetics, the basis for cutaneous tropism, the prognosis of histologic subtypes, and the role of radiotherapy.

Original languageEnglish (US)
Pages (from-to)398-405
Number of pages8
JournalJournal of Clinical Oncology
Volume19
Issue number2
StatePublished - Jan 15 2001
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Doxorubicin
Recurrence
Skin
Radiotherapy
Therapeutics
Lymphoma
Lymphoma, Large B-Cell, Diffuse
Survival
Mycosis Fungoides
Tropism
Cytogenetics
Disease-Free Survival
Prospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I : Preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. / Sarris, A. H.; Braunschweig, Ira; Medeiros, L. J.; Duvic, M.; Ha, C. S.; Rodriguez, M. A.; Hagemeister, F. B.; McLaughlin, P.; Romaguera, J.; Cox, J.; Cabanillas, F.

In: Journal of Clinical Oncology, Vol. 19, No. 2, 15.01.2001, p. 398-405.

Research output: Contribution to journalArticle

Sarris, AH, Braunschweig, I, Medeiros, LJ, Duvic, M, Ha, CS, Rodriguez, MA, Hagemeister, FB, McLaughlin, P, Romaguera, J, Cox, J & Cabanillas, F 2001, 'Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: Preferential cutaneous relapses but high cure rate with doxorubicin-based therapy', Journal of Clinical Oncology, vol. 19, no. 2, pp. 398-405.
Sarris, A. H. ; Braunschweig, Ira ; Medeiros, L. J. ; Duvic, M. ; Ha, C. S. ; Rodriguez, M. A. ; Hagemeister, F. B. ; McLaughlin, P. ; Romaguera, J. ; Cox, J. ; Cabanillas, F. / Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I : Preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 2. pp. 398-405.
@article{e0bd7639c23f4d77a843fadd7e669b30,
title = "Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: Preferential cutaneous relapses but high cure rate with doxorubicin-based therapy",
abstract = "Purpose: Establish frequency, presenting features, response and relapse patterns, and outcome of primary cutaneous non-Hodgkin's lymphoma (PCNHL). Patients and Methods: Review of untreated patients, older than 16 years, presenting between 1971 and 1993 with cutaneous lymphoma, not mycosis fungoides, and Ann Arbor stage I. Results: We identified 46 patients, 27 males, with median age of 57 years. Treatment was radiotherapy in 10 patients, doxorubicin-based therapy in 33 patients that was followed by radiotherapy in 25 patients, and other combination with radiotherapy in one patient. The complete response rate was 95{\%}. After a median follow-up of 140 months (range, 61 to 284 months), 18 patients have relapsed, and 14 have died from lymphoma. The first failure was exclusively cutaneous in 50{\%} of relapses. For the 44 treated patients, progression-free survival (PFS; actuarial ± SE) was 61{\%} ± 7{\%} and survival was 58{\%} ± 9{\%} at 12 years. For the 18 patients with diffuse large B-cell lymphoma, after doxorubicin-based regimens, PFS was 71{\%} ± 12{\%} (P = .0003) versus 0{\%} after radiotherapy; survival was 77{\%} ± 12{\%} versus 25{\%} ± 22{\%} (P = 004), respectively. For the nine patients with follicular center-cell lymphoma treated with combined modality, the 12-year PFS was 89{\%} ± 11{\%} and survival 70{\%} ± 18{\%}. Conclusion: PCNHL is rare, and its first relapse is exclusively cutaneous in 50{\%} of patients. Patients with diffuse large B-cell lymphoma are curable with doxorubicin-based regimens but not with radiotherapy. Prospective studies in PCNHL should define the cytogenetics, the basis for cutaneous tropism, the prognosis of histologic subtypes, and the role of radiotherapy.",
author = "Sarris, {A. H.} and Ira Braunschweig and Medeiros, {L. J.} and M. Duvic and Ha, {C. S.} and Rodriguez, {M. A.} and Hagemeister, {F. B.} and P. McLaughlin and J. Romaguera and J. Cox and F. Cabanillas",
year = "2001",
month = "1",
day = "15",
language = "English (US)",
volume = "19",
pages = "398--405",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I

T2 - Preferential cutaneous relapses but high cure rate with doxorubicin-based therapy

AU - Sarris, A. H.

AU - Braunschweig, Ira

AU - Medeiros, L. J.

AU - Duvic, M.

AU - Ha, C. S.

AU - Rodriguez, M. A.

AU - Hagemeister, F. B.

AU - McLaughlin, P.

AU - Romaguera, J.

AU - Cox, J.

AU - Cabanillas, F.

PY - 2001/1/15

Y1 - 2001/1/15

N2 - Purpose: Establish frequency, presenting features, response and relapse patterns, and outcome of primary cutaneous non-Hodgkin's lymphoma (PCNHL). Patients and Methods: Review of untreated patients, older than 16 years, presenting between 1971 and 1993 with cutaneous lymphoma, not mycosis fungoides, and Ann Arbor stage I. Results: We identified 46 patients, 27 males, with median age of 57 years. Treatment was radiotherapy in 10 patients, doxorubicin-based therapy in 33 patients that was followed by radiotherapy in 25 patients, and other combination with radiotherapy in one patient. The complete response rate was 95%. After a median follow-up of 140 months (range, 61 to 284 months), 18 patients have relapsed, and 14 have died from lymphoma. The first failure was exclusively cutaneous in 50% of relapses. For the 44 treated patients, progression-free survival (PFS; actuarial ± SE) was 61% ± 7% and survival was 58% ± 9% at 12 years. For the 18 patients with diffuse large B-cell lymphoma, after doxorubicin-based regimens, PFS was 71% ± 12% (P = .0003) versus 0% after radiotherapy; survival was 77% ± 12% versus 25% ± 22% (P = 004), respectively. For the nine patients with follicular center-cell lymphoma treated with combined modality, the 12-year PFS was 89% ± 11% and survival 70% ± 18%. Conclusion: PCNHL is rare, and its first relapse is exclusively cutaneous in 50% of patients. Patients with diffuse large B-cell lymphoma are curable with doxorubicin-based regimens but not with radiotherapy. Prospective studies in PCNHL should define the cytogenetics, the basis for cutaneous tropism, the prognosis of histologic subtypes, and the role of radiotherapy.

AB - Purpose: Establish frequency, presenting features, response and relapse patterns, and outcome of primary cutaneous non-Hodgkin's lymphoma (PCNHL). Patients and Methods: Review of untreated patients, older than 16 years, presenting between 1971 and 1993 with cutaneous lymphoma, not mycosis fungoides, and Ann Arbor stage I. Results: We identified 46 patients, 27 males, with median age of 57 years. Treatment was radiotherapy in 10 patients, doxorubicin-based therapy in 33 patients that was followed by radiotherapy in 25 patients, and other combination with radiotherapy in one patient. The complete response rate was 95%. After a median follow-up of 140 months (range, 61 to 284 months), 18 patients have relapsed, and 14 have died from lymphoma. The first failure was exclusively cutaneous in 50% of relapses. For the 44 treated patients, progression-free survival (PFS; actuarial ± SE) was 61% ± 7% and survival was 58% ± 9% at 12 years. For the 18 patients with diffuse large B-cell lymphoma, after doxorubicin-based regimens, PFS was 71% ± 12% (P = .0003) versus 0% after radiotherapy; survival was 77% ± 12% versus 25% ± 22% (P = 004), respectively. For the nine patients with follicular center-cell lymphoma treated with combined modality, the 12-year PFS was 89% ± 11% and survival 70% ± 18%. Conclusion: PCNHL is rare, and its first relapse is exclusively cutaneous in 50% of patients. Patients with diffuse large B-cell lymphoma are curable with doxorubicin-based regimens but not with radiotherapy. Prospective studies in PCNHL should define the cytogenetics, the basis for cutaneous tropism, the prognosis of histologic subtypes, and the role of radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0035863559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035863559&partnerID=8YFLogxK

M3 - Article

C2 - 11208831

AN - SCOPUS:0035863559

VL - 19

SP - 398

EP - 405

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -